Prevention of dementia in patients that have been vaccinated with Shingrix Mental and Behavioural Disorders
Conditions
Interventions
This study is a retrospective cohort study based on secondary use of data for select patients in Sweden who have consented to their data being used for a vaccination study and future studies with scie
Sponsors
Lumell Associates
Eligibility
Sex/Gender
All
Age
50 Years to 100 Years
Inclusion criteria
Inclusion criteria: Patients that participated in the previous vaccination studies in Sweden will be included in this study. The date of inclusion will be when the first dose of either Shingrix or placebo was administered. Patients can be included at any point during the inclusion period and the associated prescreening and follow-up period will be associated with the inclusion date. Members of the synthetic control arm will have the same inclusion date as their associated patient from the vaccination study.
Exclusion criteria
Exclusion criteria: Individuals without a Swedish personal identification number will be excluded. Individuals that have a confirmed dementia diagnosis in the pre-screening period will be excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Measured using patient records at a single time point: 1. Number of healthcare visits for patients who received the Shingrix vaccine compared to the synthetic control arm 2. Length of hospitalization for patients who received the Shingrix vaccine compared to the synthetic control arm 3. Costs of visits for patients who received the Shingrix vaccine compared to the synthetic control arm 4. Costs of treatment for patients who received the Shingrix vaccine compared to the synthetic control arm 5. Total reimbursement for sick leave for patients who received the Shingrix vaccine compared to the synthetic control arm | — |
Secondary
| Measure | Time frame |
|---|---|
| Measured using patient records at a single time point: 1. Number of healthcare visits for patients who received the Shingrix vaccine compared to the synthetic control arm 2. Length of hospitalization for patients who received the Shingrix vaccine compared to the synthetic control arm 3. Costs of visits for patients who received the Shingrix vaccine compared to the synthetic control arm 4. Costs of treatment for patients who received the Shingrix vaccine compared to the synthetic control arm 5. Total reimbursement for sick leave for patients who received the Shingrix vaccine compared to the synthetic control arm | — |
Countries
Sweden
Contacts
Public ContactJohan Sanmartin Berglund
Outcome results
None listed